Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health Ian Cooper Wed, April 22, 2026 at 12:24 PM EDT 5 min read NVO LLY Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that "2025 was probably the single most exciting year in my entire journey." The catalyst: GLP-1 medicines. His claim deserves scrutiny because the investment and personal health implications are substantial. A Trillion-Dollar Claim Worth Examining Karnal's argument has two parts. First, the commercial case: "This is a class of medicines that will easily be in excess of $100 billion a year in revenue." Second, the structural case: GLP-1 adoption is "the first commercial proof that we are ready for what I think we're gonna look back on in time as a once-in-a-lifetime trillion-dollar revolution in all of public health." He frames this not as a pharmaceutical success story but as a behavioral shift, with consumers "voting with their feet" to move from reactive disease treatment to proactive health protection. The structural case is harder to price: GLP-1 adoption as a behavioral shift toward proactive health is a compelling framework, but the timeline and policy environment remain genuinely uncertain. The Commercial Case Has Real Numbers Behind It Eli Lilly ( NYSE: LLY ) generated combined G…